Hikma Pharmaceuticals (LON:HIK) Trading Down 14.1% After Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK) shares traded down 14.1% on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares were traded during trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. reduced their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research report on Friday. Jefferies Financial Group restated a “buy” rating and set a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a research note on Friday. Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals has an average rating of “Buy” and a consensus price target of GBX 2,416.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Laura Balan Balan bought 3,500 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average cost of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah purchased 315,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was acquired at an average price of GBX 1,601 per share, with a total value of £5,043,150. Insiders bought a total of 332,500 shares of company stock valued at $533,130,500 in the last three months. Insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Trading Up 3.9%

The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The firm has a market cap of £3.50 billion, a price-to-earnings ratio of 9.47, a PEG ratio of 2.38 and a beta of 0.41. The company has a fifty day moving average price of GBX 1,730.88 and a 200-day moving average price of GBX 1,893.97.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.